|
|
Elucidation of cancer pathways and druggable targets using mouse models.
|
2U01CA084294-11
|
$835,000
|
$417,500
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Modeling androgen-independent prostate cancer in mutant mice
|
5R01CA115717-03
|
$305,900
|
$76,475
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
SPORE in Pancreatic Cancer
|
3P20CA101936-05S1
|
$521,256
|
$521,256
|
ABBRUZZESE, JAMES
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
Modeling Prostate Tumorigenesis
|
5R01CA094858-07
|
$230,554
|
$115,277
|
Abdulkadir, Sarki
|
VANDERBILT UNIVERSITY
|
|
|
Risk factors for site-specific metastasis in esophageal cancer
|
5K07CA132892-02
|
$135,351
|
$135,351
|
Abrams, Julian
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Biophysical studies of oncogenic Cdc42Hs constructs
|
5K01CA113753-03
|
$140,543
|
$140,543
|
ADAMS, PAUL
|
UNIVERSITY OF ARKANSAS AT FAYETTEVILLE
|
|
|
Radioactive Nanoparticle Immunoconjugates for the Treatment of Solid Tumors
|
5R21CA128421-03
|
$171,000
|
$171,000
|
ADAMS, GREGORY
|
FOX CHASE CANCER CENTER
|
|
|
MMC and VICC: Partners in Eliminating Cancer Disparities
|
5U54CA091408-09
|
$1,475,007
|
$221,251
|
Adunyah, Samuel
|
MEHARRY MEDICAL COLLEGE
|
|
|
Colon Cancer Chemoprevention by Flavonoid Silibinin
|
5R01CA112304-05
|
$288,389
|
$288,389
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
|
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis
|
5R01CA124940-03
|
$250,515
|
$82,670
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
|
Functional determinants of metastatic dormancy
|
5R01CA109182-06
|
$317,416
|
$317,416
|
AGUIRRE-GHISO, JULIO
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
|
Bone-seeking proteasome inhibitors for myeloma
|
5K01CA113468-05
|
$153,226
|
$38,307
|
AGYIN, JOSEPH
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
|
|
SELECT Pre-Clinical Trial of Prostate Cancer
|
5R01CA114060-04
|
$250,774
|
$250,774
|
Ahmad, Nihal
|
UNIVERSITY OF WISCONSIN MADISON
|
|
|
Phase III Trial of Selenium for Prostate Cancer Prevention
|
5R01CA077789-11
|
$607,234
|
$303,617
|
Ahmann, Frederick
|
UNIVERSITY OF ARIZONA
|
|
|
Signal Transduction Pathways in Melanoma
|
5R01CA118972-03
|
$268,547
|
$214,838
|
AHN, NATALIE
|
UNIVERSITY OF COLORADO AT BOULDER
|
|
|
Genomewide association in early-onset breast cancer
|
5U01CA122171-04
|
$1,045,578
|
$261,395
|
AHSAN, HABIBUL
|
UNIVERSITY OF CHICAGO
|
|
|
Epigenetic markers involved in colorectal cancer recurrence and metastases
|
5K23CA127141-02
|
$140,940
|
$70,470
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
|
"Genetic interactions between Tgfb1 and Skts15/Tgfbm3 in cancer"
|
5R01CA116019-03
|
$295,736
|
$73,934
|
AKHURST, ROSEMARY
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
Prevention of Metastatic Cancer Using a Novel Vitamin E Analog
|
5R01CA120552-04
|
$241,727
|
$241,727
|
AKPORIAYE, EMMANUEL
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
|
A Novel Regulator of Cancer Cell Migration and Invasion
|
5R01CA115706-04
|
$195,792
|
$195,792
|
ALAHARI, SURESH
|
LOUISIANA STATE UNIV HSC NEW ORLEANS
|
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
2P30CA023074-31
|
$4,161,907
|
$1,082,096
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
|
CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
|
3P01CA027502-27S1
|
$750,000
|
$187,500
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-31S1
|
$105,806
|
$27,510
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
|
Genomic and Functional Analysis of Oral Cancer Development
|
5R01CA118323-03
|
$270,375
|
$135,188
|
Albertson, Donna
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
Amplicons in Oral Dysplasia
|
5R01CA131286-02
|
$270,000
|
$270,000
|
Albertson, Donna
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
|
Systems Analysis of Cell Invasion Induced by Differential Mena Isoform Expression
|
1F32CA142035-01
|
$47,210
|
$47,210
|
Alford, Shannon
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
|
Assessments of Multiple Breast Cancer Biomarkers with Dendritic MRI Probes
|
1K25CA129173-01A2
|
$126,225
|
$63,113
|
Ali, Md
|
HENRY FORD HEALTH SYSTEM
|
|
|
Cellular MRI in Glioma and Radiation Necrosis
|
5R01CA122031-03
|
$247,950
|
$148,770
|
ALI, SYED
|
HENRY FORD HEALTH SYSTEM
|
|
|
Stem Cells as Delivery Vehicles and Imaging Probes for Glioma Gene Therapy
|
5R21CA129801-02
|
$195,750
|
$97,875
|
ALI, SYED
|
HENRY FORD HEALTH SYSTEM
|
|
|
Role of Vitamin D Receptor Polymorphisms in Breast Cancer
|
5F31CA132619-02
|
$35,583
|
$35,583
|
Alimirah, Fatouma
|
ILLINOIS INSTITUTE OF TECHNOLOGY
|
|
|
Blood Flow MRI for Monitoring Glioma Angiogenesis
|
5R01CA115745-04
|
|
$0
|
ALSOP, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Control of Apoptosis in Cancer by Survivin
|
2R01CA078810-12A1
|
$300,885
|
$300,885
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
|
Molecular targeting of the survivin pathway in cancer
|
5R01CA090917-10
|
$288,775
|
$288,775
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
|
AKT Function in Pancreatic Tumor Cell Invasiveness and In Vivo Pathogenesis.
|
1R21CA129302-01A2
|
$191,676
|
$191,676
|
Altomare, Deborah
|
FOX CHASE CANCER CENTER
|
|
|
The Molecular Profile of Prostate Tumors in Smokers
|
ZIA BC 010660
|
$141,957
|
$141,957
|
Ambs, Stefan
|
CCR (NCI)
|
|
|
Dietary Prevention of Cancer
|
2R01CA109269-06A1
|
$283,480
|
$70,870
|
ANANT, SHRIKANT
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
|
Dietary Prevention of Cancer
|
3R01CA109269-06A1S1
|
$58,803
|
$14,701
|
ANANT, SHRIKANT
|
UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
|
|
|
MAMMARY GLAND BIOLOGY GRC
|
5R13CA128408-03
|
$8,000
|
$8,000
|
ANDERSON, STEVEN
|
GORDON RESEARCH CONFERENCES
|
|
|
PROSTATE, LUNG, COLORECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL - SCREENING
|
N01CN025516-095
|
$1,562,516
|
$156,252
|
ANDRIOLE, GERALD
|
WASHINGTON UNIV:1107522
|
|
|
Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent
|
5K99CA131489-02
|
$132,965
|
$66,483
|
Aneja, Ritu
|
GEORGIA STATE UNIVERSITY
|
|
|
Extension of Radiotherapy Research
|
3P01CA006294-44S1
|
$300,000
|
$75,000
|
ANG, K
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
|
5K24CA128953-02
|
$164,476
|
$164,476
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
B-RAF Regulation of the Cell Cycle in Melanoma
|
5R01CA125103-03
|
$256,470
|
$256,470
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
Role of Src in Stress-Mediated Progression of Ovarian Cancer
|
5F31CA126474-03
|
$27,032
|
$27,032
|
ARMAIZ-PENA, GUILLERMO
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
|
Telomeres, Telomerase and Tumor Progression
|
5R01CA111691-05
|
$294,015
|
$147,008
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
SPORE in Breast Cancer
|
5P50CA098131-07
|
$2,300,000
|
$575,000
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
|
TGF-betas and Receptors and Human Breast Cells
|
5R01CA062212-14
|
$327,478
|
$163,739
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
|
Activated nano-sized MR contrast agents for imaging of tumor proteolytic activity
|
1R21CA133288-01A1
|
$180,400
|
$180,400
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Molecular Mechanisms of Invadopodia Formation and Function
|
5K99CA129205-02
|
$105,972
|
$105,972
|
Artym, Vira
|
GEORGETOWN UNIVERSITY
|
|
|
DF/HCC Kidney Cancer SPORE
|
2P50CA101942-06A1
|
$2,300,000
|
$667,000
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Total relevant funding to Metastasis for this search: $387,260,786
|
